The fight between policymakers intent on lowering prescription drug prices and the drugmakers who keep raising them intensified Thursday as a slew of Republican senators threatened to side with manufacturers against legislation supported by their own committee chairman and president. After months of closed-door meetings and high-profile hearings, the Senate Finance Committee voted 19-9 to advance legislation introduced by Sens. Chuck Grassley, R-Iowa, and Ron Wyden, D-Oregon, to rein in drug cos...
READ MORE
|
Kern Pharma, a leading company in the development, manufacture and production of medicines, launches Flebikern® 500 mg. This drug is indicated for the short-term relief of edema and symptoms associated with chronic venous insufficiency in adults, increasing the tone of the veins and the resistance of the capillaries (small blood vessels)....
READ MORE
|
Johnson & Johnson has dumped OSE Immunotherapeutics’ autoimmune candidate FR104. J&J picked up the rights to the CD28 antagonist for €10 million ($11 million) upfront in 2016, but clinical progress stalled following the deal. The potential for FR104 to improve outcomes in autoimmune disorders such as rheumatoid arthritis caught J&J’s attention in 2013. Back then, J&J secured an exclusive option the drug, which is designed to control T effector functions and there...
NICK PAUL TAYLOR
READ MORE
|
It feels sometimes as if Bristol-Myers Squibb’s checkpoint inhibitor Opdivo (nivolumab) is a miraculous cancer drug, given the number of indications it has been approved for. And in many ways it is. However, it apparently can’t do everything, and the company announced today that the drug failed to meet its primary endpoint in patients with newly diagnosed O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated glioblastoma multiforme (GBM), a type of brain cancer. The drug was bei...
READ MORE
|
City officials are pressing their case against drug makers and distributors for what they describe as reckless conduct that fueled the nation’s opioid epidemic. A pair of law firms representing the city recently filed a lawsuit in Middlesex Superior Court seeking damages from a range of major corporations involved in the production and sale of opioid drugs. The suit, filed Dec. 5, names as defendants pharmaceutical manufacturers and distributors, as well as some individual board members an...
READ MORE
|
Formerly the company’s chief finance officer, Hubertus von Baumbach has been in post since last June when he took over from Andreas Barner, and is overseeing strong growth....
READ MORE
|